<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03619850</url>
  </required_header>
  <id_info>
    <org_study_id>AMAG-FER-CKD-354</org_study_id>
    <nct_id>NCT03619850</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Safety (Compared to Iron Sucrose), Efficacy and Pharmacokinetics of Ferumoxytol for the Treatment of Iron Deficiency Anemia (IDA) in Pediatric Subjects With Chronic Kidney Disease (CKD)</brief_title>
  <official_title>A Phase 3, Randomized, Open-Label, Multicenter Study to Evaluate the Safety (Compared to Iron Sucrose), Efficacy and Pharmacokinetics of Ferumoxytol for the Treatment of Iron Deficiency Anemia (IDA) in Pediatric Subjects With Chronic Kidney Disease (CKD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AMAG Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AMAG Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary Objectives:

      To evaluate the safety (compared to iron sucrose) and efficacy of ferumoxytol in pediatric
      CKD subjects with iron deficiency anemia (IDA) or who are at risk of development of IDA

      Secondary Objective:

      To determine the single-dose pharmacokinetics (PK) and pharmacodynamics (PD) profile of
      ferumoxytol in pediatric subjects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase 3, randomized, open-label, multicenter, study of the safety (compared to iron
      sucrose), efficacy, and PK/PD of ferumoxytol (7.0 mg Fe/kg x 2 [max 510 mg/dose]) in
      pediatric subjects with iron deficiency anemia (IDA) and CKD. There will be a total of
      approximately 125 subjects randomized to treatment in a 2:1 ratio to either ferumoxytol or
      iron sucrose.

      Total subject participation in the study will be up to 7 weeks, which includes a 2-week
      Screening Period and a 5-week Treatment Period.

      Subjects receive the following:

      • Two IV infusions of ferumoxytol 7.0 mg Fe/kg (max 510 mg/dose), the first administered on
      Day 1 and the second 2-8 days later

      OR

      • Iron sucrose (Venofer®): For Hemodialysis Dependent (HDD) patients: 2 mg Fe/kg,
      administered on consecutive dialysis sessions, for 10 doses (max 100mg/dose with a total max
      treatment course of 1000mg) For Non-hemodialysis Dependent (NDD) or Peritoneal Dialysis De
      pendent(PDD) patients: 4 mg Fe/kg, administered up to 3 times/week, for 5 doses (max
      200mg/dose with a total max treatment course of 1000mg).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 13, 2018</start_date>
  <completion_date type="Anticipated">January 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">August 31, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hemoglobin change of at least 0.5 g/dL from Baseline to Week 5</measure>
    <time_frame>35 days</time_frame>
    <description>Proportion of patients achieving a hemoglobin change of at least 0.5 g/dL during the period from Baseline to Week 5</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of Treatment Emergent Adverse Events</measure>
    <time_frame>49 days</time_frame>
    <description>Incidence of Treatment Emergent Adverse Events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events of special interest (AESI)</measure>
    <time_frame>49 days</time_frame>
    <description>Incidence of adverse events of special interest (AESI) (hypotension and hypersensitivity)</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Area Under the Curve (AUC)</measure>
    <time_frame>35 days</time_frame>
    <description>Pharmacokinetic parameter: Area Under the Curve (AUC)</description>
  </other_outcome>
  <other_outcome>
    <measure>Clearance</measure>
    <time_frame>35 days</time_frame>
    <description>Pharmacokinetic parameter: clearance</description>
  </other_outcome>
  <other_outcome>
    <measure>Distribution and elimination half-lives</measure>
    <time_frame>35 days</time_frame>
    <description>Pharmacokinetic parameter: distribution and elimination half-lives</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">129</enrollment>
  <condition>Chronic Kidney Disease; Iron Deficiency Anemia</condition>
  <arm_group>
    <arm_group_label>Ferumoxytol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Iron sucrose</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ferumoxytol</intervention_name>
    <description>Each 20 mL single-use vial contains 17 mL of ferumoxytol that consists of iron at a concentration of 30 mg Fe/mL, coated with polyglucose sorbitol carboxymethylether and formulated with mannitol, at a concentration of 44 mg/mL, in a black to reddish brown sterile, aqueous, colloidal, isotonic solution.</description>
    <arm_group_label>Ferumoxytol</arm_group_label>
    <other_name>Feraheme</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Iron sucrose</intervention_name>
    <description>Each mL contains 20 mg of elemental iron as iron sucrose in water for injection. The 5 mL single-use vial contains 100 mg of iron per 5 mL. The drug product contains approximately 30% sucrose (300 mg/mL).</description>
    <arm_group_label>Iron sucrose</arm_group_label>
    <other_name>Venofer</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female 2 years to &lt;18 years of age at time of consent

          2. Has IDA defined as: a) hemoglobin &lt;12.0 g/dL and b) with either transferrin saturation
             (TSAT) &lt;40% or ferritin &lt;100 ng/mL; or considered to be at risk of development of IDA,
             i.e., TSAT&lt;20% with falling hemoglobin during the preceding 2 months and a history of
             hemoglobin &lt;12 g/dL

          3. Has Chronic Kidney Disease defined as one of the following:

               1. on chronic hemodialysis;

               2. receiving chronic peritoneal dialysis;

               3. estimated glomerular filtration rate (eGFR) of &lt;60 mL/min/1.73 m2;

               4. has evidence of structural and/or functional abnormalities e.g., persistent
                  albuminuria, abnormal urine sediment, electrolyte and other abnormalities due to
                  tubular disorders for &gt; 3 months.

          4. For patients other than hemodialysis dependent CKD patients, documented history of
             unsatisfactory oral iron therapy or in whom oral iron cannot be tolerated, or for whom
             oral iron is considered medically inappropriate

          5. All subjects (female and male) of childbearing potential who are sexually active must
             be on an effective method of birth control for at least 1 month prior to Day 1 Dosing
             and agree to remain on birth control until completion of the study

        Exclusion Criteria:

          1. Known hypersensitivity reaction to any component of ferumoxytol and iron sucrose

          2. History of allergy to intravenous (IV) iron

          3. History of multiple drug allergies (&gt;2)

          4. Low systolic blood pressure (Age 1-9 years &lt;70 + [age in years x 2] mmHg, Age 10-17
             years &lt;90 mmHg)

          5. Hemoglobin ≤7.0 g/dL

          6. Serum ferritin level &gt;600 ng/mL
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Clinical Trial Interest</last_name>
    <phone>1-877-233-4781</phone>
    <email>AMAGCT@druginfo.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Memorial Healthcare System</name>
      <address>
        <city>Hollywood</city>
        <state>Florida</state>
        <zip>33021</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Wayne State University</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Children's Mercy Hospital</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64108</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Montefiore Medical Center (MMC) - The Children's Hospital at Montefiore (CHAM)</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10467</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Feinstein Institute Medical Research Organization of Northwell Health, Inc.</name>
      <address>
        <city>Lake Success</city>
        <state>New York</state>
        <zip>11042</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Icahn School of Medicine at Mount Sinai (ISMMS) - The Mount Sinai Hospital (MSH)</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Akron Nephrology Associates, Inc.</name>
      <address>
        <city>Akron</city>
        <state>Ohio</state>
        <zip>44302</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>West Virginia University</name>
      <address>
        <city>Morgantown</city>
        <state>West Virginia</state>
        <zip>26506</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Semmelweis Egyetem - Altalanos Orvostudomanyi Kar (SE AOK) - I. sz. Gyermekgyogyaszati Klinika</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Of Szeged</name>
      <address>
        <city>Szeged</city>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital of Lithuanian University of Health Sciences Kauno klinikos</name>
      <address>
        <city>Kaunas</city>
        <country>Lithuania</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Klaipeda Children's Hospital</name>
      <address>
        <city>Klaipėda</city>
        <country>Lithuania</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Vsl Vilniaus Universiteto Vaiku Ligonine (VUVL) (Vilnius University Children's Hospital)</name>
      <address>
        <city>Vilnius</city>
        <country>Lithuania</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Instituto Mexicano De Trasplantes S.C</name>
      <address>
        <city>Cuernavaca</city>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>JM Research, SC</name>
      <address>
        <city>Cuernavaca</city>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Civil de Guadalajara Fray Antonio Alcalde</name>
      <address>
        <city>Guadalajara</city>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Instituto Nacional de Pediatria (INP) (National Institute of Pediatrics)</name>
      <address>
        <city>Mexico City</city>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Uniwersytecki Szpital Kliniczny Im. Zamenhofa w Bialystoku</name>
      <address>
        <city>Białystok</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Specjalistyczne Gabinety Sp. z o.o</name>
      <address>
        <city>Kraków</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Children Hospital</name>
      <address>
        <city>Kraków</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Polish Mother's Memorial Hospital Research Institute</name>
      <address>
        <city>Łódź</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>Hungary</country>
    <country>Lithuania</country>
    <country>Mexico</country>
    <country>Poland</country>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>August 3, 2018</study_first_submitted>
  <study_first_submitted_qc>August 3, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 8, 2018</study_first_posted>
  <last_update_submitted>July 14, 2020</last_update_submitted>
  <last_update_submitted_qc>July 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 15, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Iron deficiency anemia (IDA)</keyword>
  <keyword>chronic kidney disease (CKD)</keyword>
  <keyword>pediatrics</keyword>
  <keyword>ferumoxytol</keyword>
  <keyword>iron sucrose</keyword>
  <keyword>Feraheme</keyword>
  <keyword>Venofer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
    <mesh_term>Anemia</mesh_term>
    <mesh_term>Anemia, Iron-Deficiency</mesh_term>
    <mesh_term>Deficiency Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ferrosoferric Oxide</mesh_term>
    <mesh_term>Ferric Oxide, Saccharated</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

